Compare Albemarle Corp. (ALB) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albemarle Corp. vs Oscar Health Inc — how do they compare? Albemarle Corp. trades at $128.41 (market cap $15.27B), while Oscar Health Inc trades at $28.96 (market cap $8.63B). The key difference: Albemarle Corp. is the larger of the two by market cap, and Albemarle Corp. pays a 1.27% dividend while Oscar Health Inc pays none. Which is the better fit depends on your goals.
| ALB | OSCR | |
|---|---|---|
Market Cap | $15.27B | $8.63B |
Sector | Basic Materials | Health |
52-Week High | $215.62 | $32.18 |
52-Week Low | $72.58 | $10.85 |
Enterprise Value | $17.75B | $4.99B |
Dividend Yield | 1.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALB trades at $128.21, down 2.29% today, amid a mixed technical picture with bullish moving averages but overbought RSI signals. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.75, driven by improved lithium pricing and cost savings. Revenue for 2025 was $5.14B, though net income remained negative at -$510.63M. Analyst consensus is a Buy with a $184.50 price target, reflecting optimism for recovery.
Outlook is cautiously optimistic as lithium demand supports earnings growth, but Q3 guidance warns of sequential declines. Key risks include volatile lithium prices and execution challenges. The stock offers potential upside to analyst targets if operational improvements continue, but investors face margin pressure and macroeconomic headwinds.
OSCR trades at $27.97, up 1.08% today, with a bearish technical signal but strong recent earnings beats in Q1 and Q2 2026. The company reported record profitability and raised its full-year outlook, driven by membership growth and cost controls. Key support lies at $26, with resistance at $28. Revenue surged 70% year-over-year in H1 2026 to $4.9 billion, per PYMNTS on August 6, 2026.
Outlook is positive due to robust growth and margin expansion, but risks include execution challenges and competitive pressures. Analysts have a consensus price target of $32.50, with 27% buy ratings. The stock offers value with a P/S of 0.53, though net income volatility remains a concern.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Albemarle Corp.
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
